Dyadic International (DYAI) Long-Term Investments (2017 - 2026)

Dyadic International (DYAI) posted Long-Term Investments of $74812.0 for Q1 2026, up 15.88% sequentially from $64561.0 in Q3 2025.

Dyadic International (DYAI) Long-Term Investments (2017 - 2026) Analysis & Trends

Dyadic International has reported Long-Term Investments for 6 years, with the latest figure at $74812.0 in Q1 2026.

Quarterly Long-Term Investments changed N/A year-over-year to $74812.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $74812.0 (changed N/A YoY) and the FY2022 annual result came in at $284709.0, changed N/A from the prior year.
Long-Term Investments grew to $74812.0 in Q1 2026 per DYAI's latest filing, from $64561.0 in the prior quarter.
Over five years, Long-Term Investments peaked at $2.0 billion in Q1 2022 and troughed at $64561.0 in Q3 2025.
A 3-year average of $399.8 million and a median of $284709.0 in 2022 frame the typical range for Long-Term Investments.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	1.77 Bn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.17 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	372.10 Mn
10	Dyadic International	19.98 Mn	19.98 Mn	-	74,812.00

Download Data